Notable
BELRUX · Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)
Primary endpoint(s) modified
Also in this update: Primary completion pushed from Jul 2029 to Nov 2029; Enrollment reduced: 63 → 53 participants
Dennis KimPhase 2 NCT07643025 Registry history of NCT07643025 on ClinicalTrials.gov (opens the registry)
Updated